Compare Rivian Automotive, Inc. (RIVN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs TransMedics Group Inc — how do they compare? Rivian Automotive, Inc. trades at $16.04 (market cap $23.41B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Rivian Automotive, Inc. is far larger — about 7.7× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| RIVN | TMDX | |
|---|---|---|
Market Cap | $23.41B | $3.06B |
Sector | Consumer Cyclical | Technology |
52-Week High | $22.45 | $150.42 |
52-Week Low | $12.50 | $61.99 |
Enterprise Value | $23.45B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company shows improving financial trends, with revenue growing to $5.39 billion in 2025 and narrowing net losses, though it remains unprofitable. Recent news highlights strong R2 SUV demand and production ramp-up, but cash flow remains negative, and the CFO departure adds execution risk.
RIVN presents a high-risk, high-reward opportunity for growth investors betting on its EV market execution. Upside hinges on successful R2 scaling and path to profitability, while risks include cash burn, competition, and macroeconomic pressures on EV demand. Analyst sentiment is cautiously optimistic with 48% buy ratings.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
